Year archive

EMYRIA LIMITED — 2021 filings

All 94 regulatory filings released by EMYRIA LIMITED (EMD) in 2021, sourced directly from the official regulator.

94 Filings

2021 Period

2021 filings (94)

Filing	Released	Lang
Notification regarding unquoted securities - EMD 9 pages 32.5KB Share Issue/Capital Change	2021-12-30	English
Emyria appoints Sixty Two Capital as corporate advisor 2 pages 142.0KB Capital/Financing Update	2021-12-29	English
Proposed issue of securities - EMD 5 pages 28.4KB Capital/Financing Update	2021-12-29	English
Application for quotation of securities - EMD 8 pages 29.7KB Capital/Financing Update	2021-12-22	English
Notice under section 708A(5)(e) of the Corporations Act 2 pages 323.3KB Capital/Financing Update	2021-12-22	English
Emyria adds wearables to psychedelic-assisted therapy trials 5 pages 167.6KB Regulatory Filings	2021-12-19	English
Pause in Trading 1 page 110.6KB Regulatory Filings	2021-12-15	English
Trading Halt 2 pages 714.5KB Regulatory Filings	2021-12-15	English
Positive animal data for Emyrias ultra-pure CBD capsule 3 pages 239.1KB Capital/Financing Update	2021-12-14	English
Positive initial MDMA-analogue screening results 3 pages 146.5KB Regulatory Filings	2021-12-07	English
Change of Director's Interest Notice KS 2 pages 248.7KB Director's Dealing	2021-12-06	English
Application for quotation of securities - EMD 9 pages 32.2KB Share Issue/Capital Change	2021-12-05	English
Application for quotation of securities - EMD 8 pages 29.8KB Share Issue/Capital Change	2021-11-30	English
Application for quotation of securities - EMD 8 pages 29.7KB Share Issue/Capital Change	2021-11-30	English
Notice under section 708A(5)(e) of the Corporations Act 2 pages 323.0KB Capital/Financing Update	2021-11-30	English
Initial Director's Interest Notice KS 2 pages 140.1KB Director's Dealing	2021-11-29	English
Emyria Anoints Global Pharma Expert Dr Karen Smith to Board 4 pages 164.6KB Board/Management Information	2021-11-28	English
Emyria Appoints Global Pharma Expert Dr Karen Smith to Board 4 pages 164.6KB Board/Management Information	2021-11-28	English
Change in substantial holding CD 3 pages 108.7KB Major Shareholding Notification	2021-11-25	English
Change in substantial holding MT 3 pages 106.6KB Major Shareholding Notification	2021-11-25	English
Change in substantial holding MW 3 pages 138.5KB Major Shareholding Notification	2021-11-25	English
Change in substantial holding SW 3 pages 114.1KB Major Shareholding Notification	2021-11-25	English
Becoming a substantial holder TAT 2 pages 106.2KB Major Shareholding Notification	2021-11-24	English
Emyria receives $1,162,000 R&D Tax Incentive Refund 2 pages 141.9KB Capital/Financing Update	2021-11-23	English
Notice under section 708A(5)(e) of the Corporations Act 2 pages 323.7KB Share Issue/Capital Change	2021-11-23	English
Application for quotation of securities - EMD 8 pages 29.6KB Share Issue/Capital Change	2021-11-23	English
Notification regarding unquoted securities - EMD 9 pages 32.3KB Share Issue/Capital Change	2021-11-23	English
Emyria Welcomes Tattarang as Strategic Investor 5 pages 237.7KB Capital/Financing Update	2021-11-21	English
Proposed issue of securities - EMD 6 pages 31.4KB Capital/Financing Update	2021-11-21	English
Application for quotation of securities - EMD 8 pages 29.8KB Share Issue/Capital Change	2021-11-21	English
Trading Halt 2 pages 721.1KB Capital/Financing Update	2021-11-18	English
Results of Meeting 2 pages 147.1KB Declaration of Voting Results & Voting Rights Announcements	2021-11-02	English
Notification regarding unquoted securities - EMD 8 pages 31.0KB Share Issue/Capital Change	2021-10-31	English
Appendix 4C - Quarterly 10 pages 337.8KB Interim / Quarterly Report	2021-10-25	English
MDMA Analogue Development Milestone 3 pages 139.3KB Regulatory Filings	2021-10-18	English
Notification of cessation of securities - EMD 6 pages 26.2KB Share Issue/Capital Change	2021-10-17	English
Notification of cessation of securities - EMD 6 pages 26.2KB Share Issue/Capital Change	2021-10-17	English
Notification of cessation of securities - EMD 6 pages 26.1KB Share Issue/Capital Change	2021-10-17	English
Notification regarding unquoted securities - EMD 7 pages 30.2KB Share Issue/Capital Change	2021-10-07	English
Emyria selected to join Palantirs Foundry Builders Program 6 pages 397.6KB Regulatory Filings	2021-10-06	English
Annual Report to shareholders 102 pages 3.4MB Annual Report	2021-09-30	English
EMD Welcomes TGA-Commissioned Report on MDMA and Psilocybin 3 pages 146.6KB Regulatory Filings	2021-09-30	English
Notice of Annual General Meeting/Proxy Form 21 pages 823.2KB AGM Information	2021-09-29	English
Letter to Shareholders - Annual General Meeting 3 pages 827.4KB AGM Information	2021-09-29	English
Appendix 4G 13 pages 290.8KB Regulatory Filings	2021-09-29	English
Lifesciences Webinar Presintation 30 pages 4.3MB Investor Presentation	2021-09-27	English
Notification regarding unquoted securities - EMD 7 pages 30.0KB Share Issue/Capital Change	2021-09-21	English
Novel MDMA Analogue Screening Program Advanced 3 pages 146.1KB Regulatory Filings	2021-09-21	English
Emyria Expands Psychiatry Advisory for Psychedelics and MDMA 4 pages 272.2KB Regulatory Filings	2021-09-15	English
MDMA-analogues Show Promise for Parkinson's Disease 6 pages 434.5KB Capital/Financing Update	2021-08-31	English
Annual General Meeting 2 pages 128.7KB AGM Information	2021-08-30	English
Appendix 4E and Full Year Statutory Accounts 60 pages 1.4MB Annual Report	2021-08-30	English
Emyria Engages Calvert Labs for Preclinical CBD studies 3 pages 145.4KB Capital/Financing Update	2021-08-26	English
Emyria Drug Development Overview and Webinar 48 pages 6.2MB Investor Presentation	2021-08-22	English
Emyria Appoints Expert Neuropharmacologist for MDMA Program 3 pages 144.9KB Board/Management Information	2021-08-19	English
Emyria Executes Pure CBD Agreement with AltaSciences 4 pages 151.9KB Capital/Financing Update	2021-08-12	English
Emyria to Develop Novel Psychedelics Pipeline with UWA 5 pages 161.9KB Regulatory Filings	2021-08-04	English
Appendix 4C - Quarterly 10 pages 491.8KB Regulatory Filings	2021-07-27	English
Principal Investigator Appointed to lead Emyria MDMA trial 3 pages 175.2KB Regulatory Filings	2021-06-28	English
Investor Webinar Presentation Today 2 pages 133.3KB Investor Presentation	2021-06-17	English
Webinar Presentation 25 pages 5.5MB Investor Presentation	2021-06-17	English
Results of Meeting 3 pages 147.7KB Declaration of Voting Results & Voting Rights Announcements	2021-06-17	English
Emyria Advances EMD-004 Program Towards Registration 3 pages 148.0KB Regulatory Filings	2021-06-14	English
Emyria Data Validated, Care Model Reduces Opioids 31 pages 10.9MB Investor Presentation	2021-06-06	English
Emyria Investor Webinar 2 pages 136.0KB Investor Presentation	2021-06-06	English
Details of Company Address 1 page 79.3KB Regulatory Filings	2021-05-18	English
Notice of General Meeting/Proxy Form 23 pages 797.2KB Proxy Solicitation & Information Statement	2021-05-16	English
Emyria Obtains TGA Approval for Medical Grade Monitoring App 4 pages 447.2KB Regulatory Filings	2021-05-11	English
Trading Halt 2 pages 519.2KB Regulatory Filings	2021-05-10	English
Emyria and MMA launch MDMA-assisted therapy program for PTSD 6 pages 185.8KB Regulatory Filings	2021-05-04	English
Appendix 4C - Quarterly 12 pages 884.7KB Capital/Financing Update	2021-04-27	English
Appendix 2A and Notice Under Section 708A 16 pages 372.3KB Capital/Financing Update	2021-04-27	English
$5m Placement for Drug Registration and Treatment Pipeline 3 pages 147.4KB Capital/Financing Update	2021-04-20	English
Proposed issue of Securities - EMD 7 pages 32.4KB Capital/Financing Update	2021-04-20	English
Proposed issue of Securities - EMD 6 pages 29.4KB Capital/Financing Update	2021-04-20	English
Trading Halt 2 pages 380.8KB Capital/Financing Update	2021-04-18	English
Emyria Drug Registration Model - EMD-003 snapshot 24 pages 4.9MB Investor Presentation	2021-04-06	English
Appendix 3G 12 pages 275.9KB Share Issue/Capital Change	2021-03-17	English
Emyria CEO in multiple webinars -Wednesday 10th March 2 pages 134.0KB Regulatory Filings	2021-03-07	English
General Meeting Shareholder Update 27 pages 6.1MB Investor Presentation	2021-03-04	English
Results of Meeting 3 pages 135.0KB Declaration of Voting Results & Voting Rights Announcements	2021-03-04	English
Emyria Adds Second Clinical Site in Perth 2 pages 247.8KB Regulatory Filings	2021-03-01	English
Half Yearly Report and Accounts 32 pages 922.9KB Interim / Quarterly Report	2021-02-23	English
Proposed issue of Securities - EMD 6 pages 29.5KB Capital/Financing Update	2021-02-21	English
Global Pharmaceutical Expert joins Advisory Board 3 pages 163.0KB Board/Management Information	2021-02-21	English
Emyria adds second Emerald Clinic in Melbourne 3 pages 184.5KB Capital/Financing Update	2021-02-08	English
Emyria wins digital health monitoring grant with UWA 3 pages 146.6KB Capital/Financing Update	2021-02-04	English
Change in substantial holding SW 5 pages 218.4KB Major Shareholding Notification	2021-02-02	English
Notice of General Meeting/Proxy Form 23 pages 827.0KB Proxy Solicitation & Information Statement	2021-02-02	English
Letter to Shareholders - General Meeting 2 pages 322.2KB Proxy Solicitation & Information Statement	2021-02-02	English
Emyria adds consultant psychiatrist to Medical Advisory 3 pages 158.9KB Board/Management Information	2021-01-31	English
FDA Position on RWE to Guide Registration 6 pages 170.8KB Regulatory Filings	2021-01-26	English
Appendix 4C - Quarterly 14 pages 842.4KB Interim / Quarterly Report	2021-01-18	English
Emyria Pursuing Registration of EMD-003 in CY2021 3 pages 148.8KB Capital/Financing Update	2021-01-04	English